Singapore, 29 February 2016 – ASLAN Pharmaceuticals (ASLAN), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced the appointment of Andrew Howden as an Independent Non-Executive Director.
Mr Howden is a senior pharmaceutical executive with almost 35 years of experience from the global pharmaceutical industry and has established a strong track record in clinical research, business development and commercialisation. Most recently, he was Chief Executive Officer of iNova Pharmaceuticals in Australia where he led an active business development strategy until its acquisition by Valeant Pharmaceuticals International. Andrew oversaw the integration of iNova Pharmaceuticals and led the expansion of the company's Asia Pacific operations until 2015. Prior to iNova Pharmaceuticals, Andrew was President of IMS Health's Asia Pacific region, Regional Vice President Asia Pacific at AstraZeneca, and held senior roles at Quintiles in Europe and Asia. Mr Howden holds a Bachelor of Science degree and a Masters of Commerce from the University of New South Wales, Australia.
Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals said: "We are delighted to welcome Andrew to ASLAN's Board of Directors. His global perspective, clinical expertise and commercial acumen will complement the skillset of our international Board. We look forward to Andrew's contributions as we focus on the late stage development of our lead asset, varlitinib (ASLAN001), and look to growing our presence in the Asia Pacific region and beyond."
Ends
Media contacts Emma Thompson / Stephanie Tan Spurwing Communications Tel: +65 9107 5559 Email: [email protected]
About ASLAN Pharmaceuticals ASLAN Pharmaceuticals is an oncology focused biotechnology company developing a portfolio of immunotherapies and targeted drugs, focusing on Asia prevalent tumour types. Led by a highly experienced management team with global pharmaceutical expertise, ASLAN is headquartered in Singapore with a platform which reaches across the region via its offices in Taiwan, China and Australia, enabling the Company to conduct and support regional clinical development programmes. The Company's proprietary pipeline of 4 development-stage candidates addresses multiple indications including gastric and breast cancers and inflammatory diseases. ASLAN's most advanced compounds are in phase 2: varlitinib (ASLAN001), a pan-HER inhibitor with phase 2 data in gastric cancer, being developed in cholangiocarcinoma, breast cancer and gastric cancer; and ASLAN002, which targets RON, an immune checkpoint inhibitor, and cMET. www.aslanpharma.com